Related Experiment Videos
Interference by antiarrhythmic agents with function of electrical cardiac devices.
1Department of Medicine, University of Illinois, College of Pharmacy, Chicago 60612.
Clinical Pharmacy
|January 1, 1992
Summary
Certain drugs can interfere with implanted cardiac devices. Adjusting device settings may be necessary to ensure proper function and patient safety when using these medications.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Implanted electrical cardiac devices, such as pacemakers and automatic implantable cardioverter-defibrillators (AICDs), are crucial for managing cardiac arrhythmias.
- Drug interactions with these devices can potentially compromise their efficacy and patient safety.
Observation:
- A patient with a pacemaker experienced high-grade atrioventricular block and pacemaker capture failure after initiating flecainide therapy.
- Another patient with an AICD required increased energy for ventricular fibrillation termination and experienced increased pacing thresholds after starting moricizine.
Findings:
- Flecainide therapy was associated with pacemaker malfunction in one patient, which was resolved by increasing the device's pulse amplitude and width.
- Moricizine therapy in another patient led to a higher energy requirement for AICD shocks and increased pacing thresholds, as evidenced by electrophysiologic studies.
Implications:
- This highlights the critical need for careful monitoring of patients with implanted cardiac devices who are prescribed potentially interacting medications.
- Adjustments to device parameters may be necessary to maintain optimal device function and prevent adverse events in the presence of certain drug therapies.